Grand Opening of the Pre-Filled Syringe Production Line

We have officially launched our third production line, which focuses on the manufacturing of pre-filled syringes for patients with rheumatoid arthritis, psoriasis, and Crohn’s disease. This technology is the first of its kind in the Czech Republic and Slovakia, and within two years, the company will be capable of meeting global demand for this type of injectable medication.

Modern Technology for At-Home Therapy

The annual capacity of the new line exceeds 100 million units and meets the highest pharmaceutical standards. Key features include a continuous filling system that enables high-speed production, automatic optical inspection, and sterile manufacturing within an isolator environment.

Our parent company, medac, is a global leader in this field and, thanks to the large production volume, is able to offer these treatments at an affordable price for all patients within the EU.

“The production of pre-filled syringes on the third line at oncomed is an example of an integrated European supply chain. The active pharmaceutical ingredient comes from Germany and Finland, while the pre-filled syringes themselves are produced in Thuringia, Germany, or in France. In Brno, they are filled in sterile conditions, assembled into autoinjectors (pens), and the final packaging takes place in Germany. Our target markets are EU countries. Strengthening European self-sufficiency is one of our long-term goals,” said Filip Vrubel, Executive Director of the Czech Association of Pharmaceutical Companies (ČAFF).

The ceremonial launch of the new production line was attended by Minister of Health Vlastimil Válek, Brno Mayor Markéta Vaňková, representatives of the South Moravian Region and the City of Brno, as well as leaders from Czech universities and secondary schools.

“This third production line marks a significant step in our growth and innovation journey. We are proud to have brought cutting-edge technology for the production of pre-filled syringes to Brno. These small-volume syringes are primarily used in autoinjectors, which allow patients to administer medication more easily and comfortably, improving disease management,” said Radek Fialka, Commercial Director and Board Member at oncomed manufacturing.

Large-volume syringes present new opportunities for expanding outpatient and home care. In situations where hospitalization was previously required—often due to the need for intravenous infusions—these can now be replaced by slow subcutaneous injections administered in clinics or at home using autoinjectors. This not only enhances patient comfort but also reduces costs for the healthcare system.

“This new production line will allow us to supply global markets, and together with our sister company in Germany, position ourselves as a major player in the pre-filled syringe sector. Our medicinal products are examples of modern, value-added generics that support patients worldwide,” said Gerhard Wurzer, Chairman of the Board.